Abstract
Much remains unknown about statin-associated muscle symptoms (SAMS) despite over 30 years of consistently expanding statin use. This is likely due to confounding factors that mimic or exaggerate true SAMS, such as the nocebo effect, medication use, aging, and disease. Study design issues have also limited the understanding of SAMS. Future studies should query participants specifically about muscle complaints and verify SAMS more rigorously. There is also a need for multidisciplinary research to better diagnose and treat SAMS so that accurate biomarkers and uniform treatment strategies are developed and validated. Addressing these needs is critical for improving statin effectiveness so that it parallels statin use.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of Evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580–90.
Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238:329–35.
Penson PE, Mancini GBJ, Toth PP, Martin SS, Watts GF, Sahebkar A, et al. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9:1023–33.
Lakey WC, Greyshock NG, Kelley CE, Siddiqui MA, Ahmad U, Lokhnygina YV, et al. Statin intolerance in a referral lipid clinic. J Clin Lipidol. 2016;10:870–879.e3.
Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016;37:908–16.
Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association’s Muscle Safety Expert, Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S58–71.
Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6–15.
Taylor BA, Panza G, Thompson PD. Increased creatine kinase with statin treatment may identify statin-associated muscle symptoms. Int J Cardiol. 2016;209:12–3.
Taylor BA, Sanchez RJ, Jacobson TA, Chibedi-De-Roche D, Manvelian G, Baccara-Dinet MT, et al. Application of the statin-associated muscle symptoms-clinical index to a randomized trial on statin myopathy. J Am Coll Cardiol. 2017;70:1680–1.
Joy TR, Monjed A, Zou GY, Hegele RA, McDonald CG, Mahon JL. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160:301–10.
Mefford MT, Tajeu GS, Tanner RM, Colantonio LD, Monda KL, Dent R, et al. Willingness to be reinitiated on a statin (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol. 2018;122:768–74.
Tanner RM, Safford MM, Monda KL, Taylor B, O’Beirne R, Morris M, et al. Primary care physician perspectives on barriers to statin treatment. Cardiovasc Drugs Ther. 2017;31:303–9.
Campione JR, Sleath B, Biddle AK, Weinberger M. The influence of physicians' guideline compliance on patients’ statin adherence: a retrospective cohort study. Am J Geriatr Pharmacother. 2005;3:229–39.
Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016;32:S35–65.
Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017;70:1290–301.
Panza GA, Taylor BA, Thompson PD. An update on the relationship between statins and physical activity. Curr Opin Cardiol. 2016;31:572–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Taylor, B.A., Thompson, P.D. (2020). Conclusions and Future Directions. In: Thompson, P., Taylor, B. (eds) Statin-Associated Muscle Symptoms. Contemporary Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-33304-1_21
Download citation
DOI: https://doi.org/10.1007/978-3-030-33304-1_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-33303-4
Online ISBN: 978-3-030-33304-1
eBook Packages: MedicineMedicine (R0)